Higher cardiovascular risk scores and liver fibrosis risk estimated by biomarkers in patients with metabolic-dysfunction-associated fatty liver disease

作     者：Giovanni Alejandro Salgado Alvarez Samanta Mayanin Pinto Galvez Uriel Garcia Mora Ana Delfina Cano Contreras Cristina Durán Rosas Bryan Adrián Priego-Parra Arturo Triana Romero Mercedes Amieva Balmori Federico Roesch Dietlen Sophia Eugenia Martinez Vazquez Ines Osvely Mendez Guerrero Luis Alberto Chi-Cervera Raúl Bernal Reyes Leonardo Alberto Martinez Roriguez Maria Eugenia Icaza Chavez Jose Maria Remes Troche 

作者机构：Instituto de Investigaciones Médico-biologicasUniversidad VeracruzanaVeracruz 91700VeracruzMexico Department of GastroenterologíaInstituto Nacional de Ciencias Médicas y Nutrición Salvador ZubiránMéxico 14080MéxicoMexico Clínica de Especialidades Gastrointestinales y HepáticasHospital Star MedicaMerida 97133YucatanMexico Department of GastroenterologiaSociedad Española de BeneficenciaPachuca 42000HidalgoMexico Department of GastroenterologiaClínica de Rehabilitación Metabólica Digestiva y HepáticaMexico 14080MexicoMexico Department of GastroenterologiaHospital Star Médica de MéridaMerida 97133YucatanMexico 

出 版 物：《World Journal of Hepatology》 (世界肝病学杂志（英文版）（电子版）)

年 卷 期：2022年第14卷第8期

页      面：1633-1642页

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

基　　金：Supported by Asociación Mexicana de Gastroenterología No.2020-001 

主　　题：Fatty liver Cardiovascular risk Hepatic steatosis Fibrosis Liver disease 

摘      要：BACKGROUND The definition of metabolic-dysfunction-associated fatty liver disease(MAFLD)allows identification of metabolically complicated *** risk scores are related to cardiovascular risk(CVR)scores and could be useful for the identification of patients at risk of systemic *** To evaluate the relationship between MAFLD and CVR using the Framingham risk score in a group of Mexican *** Cross-sectional,observational and descriptive study carried out in a cohort of 585 volunteers in the state of Veracruz with MAFLD *** risk of liver fibrosis was calculated with aspartate aminotransferase-to-platelet ratio index,nonalcoholic fatty liver disease score and fibrosis-4,as well as with transient hepatic elastography with Fibroscan~?.The CVR was determined by the Framingham *** One hundred and twenty-five participants(21.4%)with MAFLD criteria were evaluated,average age 54.4 years,63.2%were women,body mass index 32.3 kg/m~*** Framingham CVR was high in 43 patients(33.9%).Transient elastography was performed in 55.2%of volunteers;39.1%with high CVR and predominance in advanced fibrosis(F3–F4).The logistic regression analysis showed that liver fibrosis,diabetes and hypertension independently increased *** One of every three patients with MAFLD had a high CVR,and in those with high fibrosis risk,the CVR risk was even greater.